Biotechnology for a Conservative Japanese Drug Industry
Japanese drug companies remain high conservative, reluctant to expand beyond a national or regional focus to create worldwide pharmaceutical businesses. More are turning to biotech collaborations to provide new products, particularly favoring combinatorial chemistry deals which are relatively inexpensive and have short-term payoffs.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.